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We present a case of an 87-year-old female who was evaluated for an 8.5 cm left sided renal mass
concerning for malignancy. The patient was transiently thrombocytopenic over the previous 4 months
with platelet counts ranging from 50,000 to 125,000 plt/mcL and experienced diffuse hemorrhage during
radical nephrectomy with failure to achieve mechanical hemostasis or fulguration. Following Surgicel
(Ethicon; Somerville, New Jersey) application, we applied Tisseel (Baxter; Deerﬁeld, IL) to the ne-
phrectomy bed with complete hemostasis of bleeding foci. Tisseel saved this thrombocytopenic patient
with uncontrolled bleeding and should have this clinical utility recognized.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Preoperative thrombocytopenia typically can be managed with
careful surgical technique and meticulous hemostasis. There is a
paucity of information on how such surgery and potential bleeding
should be managed in patients with an underlying thrombocyto-
penia and/or coagulopathy.1 In the case of a patient with chronic
thrombocytopenia, ﬁbrin sealants may provide superior cessation
of oozing at the surgical bed in radical organ resection.Figure 1. T1 MRI cross section showing a necrotic heterogeneously enhancing exo-
phytic mass in the lower pole of the left kidney measures approximately 5.1 cm
AP  4.5 cm TR  5.1 cm CC, consistent with renal cell carcinoma.Case presentation
An 87-year-old female presented to the urology clinic with an
incidental 8.5 cm renal mass onMRI imaging (Fig. 1). There were no
signs of local extension outside of the kidney, renal vessel
involvement or signs of metastases. The patient was subsequently
counseled and consented for radical nephrectomy. Routine blood
analysis was performed and revealed a persistent thrombocyto-
penia with a platelet count of 84,000 (150,000e350,000 plt/mcL).
The patient’s thrombocytopenia was suspected to be chronic and
she was worked up by a hematologist who ordered a bone marrow
biopsy. This showed no sign of myelodysplasia and normal trili-
neage hematopoiesis, cytogenetics, and ﬂow cytometry. Followinglogy, Mofﬁtt Cancer Center,
, USA.
iess).
access article under the CC BY-NC-workup, she was cleared for surgery by the hematologist,
anesthesiologist, and primary surgical team. The morning of the
nephrectomy our patient’s platelet count was 57,000 (150,000e
350,000 plt/mcL) at 6:15 am. We ensured she was a properly typedND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 2. The role of Tisseel in the clotting cascade.
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require transfusion.
We approached our patient using a modiﬁed ﬂank approach
with a laparoscopic hand-assisted technique. The entire kidney was
mobilized after necessary exposure was undertaken and suitable
surgical planes were developed. The renal vascular hilum was
skeletonized consisting of single renal artery and vein, which were
controlled with the endovascular stapler in a standard procedure.
The left adrenal gland was also removed en bloc with the specimen
due to concerns for invasion. At this point, numerous small but
diffuse areas from the surgical bed started oozing blood. These
areas were difﬁcult to control to standard surgical techniques.
Floseal (Baxter; Deerﬁeld, IL) and Surgicel were utilized before
proceedingwith furthermobilization of the renal hilum. The kidney
was easily removed from the hand-assist port site, which was fol-
lowed by some persistent bothersome diffuse oozing. It was at this
time that we elected to convert to an open approach.
Once we converted to open, persistent diffuse oozing was pre-
sent throughout the retroperitoneal surgical bed, more than ex-
pected for this procedure. Intraoperative blood serology including
coagulation parameters were sent. We decided to administer a
platelet transfusion as a precaution given her known thrombocy-
topenia. Her intraoperative platelet count was 64,000 at 11:39 am.
Due to persistent bleeding, Tisseel was used and was quite effective
in achieving fairly instantaneous hemostasis. Following completion
of the surgery the patient was determined to be hemodynamically
stable and was extubated by anesthesia without incident.
Estimated blood loss of the operationwas 900 cc and the patient
received 580 cc platelets, 550 cc packed red blood cells, 350 cc fresh
frozen plasma, 1100 cc of Plasma-lyte, and 500 cc Voluven 6:1
normal saline. A total of 580 cc of platelets were transfused, which
ultimately brought the patient’s post-operative platelet count to
117,000. Repeat analyses revealed her platelet count returned to
near baseline levels of 69,000 at 23:18 pm. On post-operative day 1,
the platelets remained stable at 69,000. Despite a return to her
baseline chronic thrombocytopenia, she remained hemodynami-
cally stable throughout her hospitalization until discharge. She was
discharged 6 days later as she began ambulating, regained bowel
function with regular diet.
Discussion
Despite use of ﬁbrinogen for adhesion in the early 1900s, FDA
approval in the United States of ﬁbrin sealants was delayed until
1998. Tisseel is a two-component ﬁbrin sealant made from pooled
human plasma that has been indicated for use in patients when
traditional methods of attaining hemostasis fail to control bleeding.
This agent acts on the ﬁnal step in the clotting cascade, shown in
(Fig. 2), with the components of ﬁbrin and thrombin serving as the
main components of this sealant to promote ﬁbrin cross linking and
thrombus formation over the platelet plug. One factor in thrombus
formation involves the ampliﬁcation of platelets into so-called
“coated platelets”.2 The stickiness of the platelet surface increases
when covered with ﬁbrin, thrombospondin-1, VWF, and Factor Va.2
The patient in question may have improved her bleeding control
due to the inﬂux of ﬁbrin and thrombin to the clot site in the settingof limited platelet availability. Clots formed by Tisseel offered total
resistance to proteolysis at 4 days, while other ﬁbrin sealants were
totally solubilized in 2 days or less. In a patient with stable and
persistent thrombocytopenia, we believe Tisseel would be the
safest option to offer the greatest uninterrupted healing time in a
high-risk patient before dissolution of the developed clot. Fibrin
glue has also been used as a hemostatic agent in patients with
coagulation disorders and in many cases of surgical hemostatic
control for deep and superﬁcial renal parenchymal bleeding.3 These
ﬁbrin products do not depend on adequacy of platelet or clotting
factors suggesting that Tisseel may be used for thrombocytopenia
due to the ﬁbrin component.
Tisseel’s properties led to a number of trials for its use for other
surgical procedures. A study by Campanelli et al showed beneﬁts in
pain, numbness, and discomfort when Tisseel was used as opposed
to sutures in mesh ﬁxation for Lichtenstein inguinal hernia repair.4
These studies indicated functional hemostasis and control with
focal use of the ﬁbrin sealant in this surgery despite the setting of
increased tissue tension. In large cases such as groin dissection,
however, Tisseel did not reduce morbidity.5 Thus, radical ne-
phrectomy in the setting of patients with known bleeding coagu-
lopathies may now be another indication.Conclusion
For thrombocytopenics, Tisseel should be made available for
difﬁcult and coagulopathic bleeding.Consent
Written informed consent was obtained from the patient for
publication of this Case Report and all accompanying images. A
copy of the written consent is available for review by the Editor-in-
Chief of this journal.Disclosure
The authors of this manuscript have no conﬂicts of interest to
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